28.20
+0.89%
Close of 9 Nov 2026, in DKK
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Embla Medical hf
Its shares trade on Nasdaq Copenhagen under the ticker EMBLA.CO. It has been listed since 1 January 2009. In the fiscal year to 31 December 2025, it reported revenue of $963.6m and net income of $86.5m. At that date it held total assets of $1.74bn and shareholders' equity of $888.6m.
Össur hf engages in the design, development, manufacture, and sale of non-invasive orthopedic products. The firm is active in the development and distribution of products in the fields of non-invasive prosthetics, medical braces and supports. The firm is divided into three market segments: Bracing and Supports, which offers products for therapeutic and preventive purposes; Prosthetics, which offers products for amputees, which include sockets, sleeves, prosthetic knees and feet, as well as supporting components, and Compression Therapy, which offers treatment for venous ulcers and edema. The firm's main markets are North America, Europe and Asia. The company has subsidiaries in Iceland, the United States, Canada, Mexico, France, the Netherlands, the United Kingdom, Sweden, Norway, Spain, South Africa, China and Australia.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Health Care Equipment & Supplies
- Listed since
- 1 Jan 2009
- Employees
- 3,449
- Website
- ossur.com/corporate ↗
Leadership
Pay as last reported
- Mr. Niels JacobsenChairman of the Board$111,000
- Mr. Sveinn SoelvasonPresident, Chief Executive Officer$1.0m
- Dr. Svafa GroenfeldtVice Chairman of the Board$74,000
- Mrs. Gudny SveinsdottirChief Financial Officer
- Mr. Christian RobinsonPresident Americas & Global Bracing, since 2024
- Mr. Lukas MaerklinChief Operating Officer
- Ms. Margret FridriksdottirExecutive Vice President - People, Strategy and Sustainability
- Mr. Olafur GylfasonExecutive Vice President - Chronic Solutions, since 2024$610,000
- Mr. Andre RochaExecutive Vice President - Research and Development
- Mr. Arne NielsenDirector$52,000
- Dr. Alberto EsquenaziIndependent Director$44,000
- Ms. Tina OlesenIndependent Director$37,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 89
- Environment
- 99
- Social
- 99
- Governance
- 69
- Direct emissions (scope 1)
- 2,460 t
- Energy emissions (scope 2)
- 3,990 t
- Value chain emissions (scope 3)
- 103,850 t
- Women in the workforce
- 50%
- Carbon reduction policy
- Yes
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Ossur hf has several strengths that contribute to its competitive advantage. These include:
Weaknesses
- Despite its strengths, Ossur hf also faces certain weaknesses that can hinder its growth and success:
Opportunities
- Ossur hf can capitalize on various opportunities to further expand its business and improve its market position:
Threats
- Ossur hf faces certain threats that can negatively impact its performance and competitive position:
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.